The global leadless pacemakers market is anticipated to grow at a CAGR of 15.3% during the forecast period (2023-2030). The market growth is attributed to factors including the changing sedentary lifestyle, smoking, and excessive alcohol consumption attributed to the prevalence of bradycardia. According to a report titled "Bradycardia and Heart Rate Fluctuation Are Associated with a Prolonged Intensive Care Unit Stay in Patients with Severe COVID-19," bradycardia was identified in 72.1% of the patients admitted to the intensive care unit at Chiang Mai University Hospital between April and June 2021. These health conditions often necessitate the use of Leadless Pacemakers to maintain an optimal heart rate. According to the Cleveland Clinic, in 2022, the prevalence of sinus bradycardia increased with age overall, impacting 1 in 600 cardiac patients over 65 years of age and 1 in 1000 persons over 45. Moreover, the significant burden of disease, high prevalence, and mortality rates are anticipated to propel the segment growth. In addition, the rising number of FDA approval also bolstering the leadless pacemakers market growth.
Browse the full report description of “Leadless Pacemakers Market Size, Share & Trends Analysis Report by Pacing Chamber (Single-chamber Pacemaker, Dual-chamber Pacemaker), By Product, (Micra Transcatheter Pacing System and Nanostim Leadless Pacemaker), by End-use (Hospitals, Ambulatory Surgical Centers, and Others), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/leadless-pacemakers-market
• In July 2023, Abbott Laboratories received the US Food and Drug Administration (FDA) approval the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms.
• In May 2023, Medtronic plc, a pioneer in healthcare technology, received US Food and Drug Administration (FDA) approval of its Micra™ AV2 and Micra™ VR2, the next generation of its industry-leading miniaturized, leadless pacemakers. Micra AV2 and Micra VR2, the world's smallest pacemakers, provide longer battery life and easier programming than prior Micra pacemakers, while still delivering the many benefits of leadless pacing such as reduced complications compared to traditional pacemakers.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Pacing Chamber
o By Product
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Competitive Landscape- includes Abbott Laboratories, Boston Scientific Corp., Medtronic plc, MicroPort Scientific Corp., Lepu Medical Technology (Beijing)Co., Ltd., and others.
Key questions addressed by the report
Global Leadless Pacemakers Market Report Segment
By Pacing Chamber
By Product
By End-User
Global Leadless Pacemakers Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/leadless-pacemakers-market